Lidocaine treatment in pediatric convulsive status epilepticus

Pediatrics International

Volumn 50, Issue 1, 2008, Pages 35-39

  Yildiz, Bilal ^a   Çitak, Agop ^b   Uçsel, Raif ^b   Karaböcüoǧlu, Metin ^b   Aydinli, Nur ^b   Uzel, Nedret ^b  

^a ESKISEHIR OSMANGAZI UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Children; Convulsive status epilepticus; Infection; Lidocaine; Treatment

Indexed keywords

ANTICONVULSIVE AGENT; DIAZEPAM; LIDOCAINE; MIDAZOLAM; PARALDEHYDE; PHENOBARBITAL; PHENYTOIN; THIOPENTAL;

ANTICONVULSANT THERAPY; ARTICLE; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONVULSIVE STATUS EPILEPTICUS; DRUG EFFICACY; EPILEPTIC STATE; FEMALE; GRAND MAL SEIZURE; HEART VENTRICLE ARRHYTHMIA; HUMAN; INFECTION; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SINGLE DRUG DOSE; TREATMENT OUTCOME;

ANTICONVULSANTS; CHILD, PRESCHOOL; FEMALE; HUMANS; LIDOCAINE; MALE; STATUS EPILEPTICUS;

EID: 39049148521     PISSN: 13288067     EISSN: 1442200X     Source Type: Journal    
DOI: 10.1111/j.1442-200X.2007.02510.x     Document Type: Article

References (33)

1. Working Group on Status Epilepticus, Epilepsy Foundation of America. Treatment of convulsive status epilepticus. JAMA 1993 270 : 854 9.
2. Maytal J, Shinnar S, Moshe SL, Alvarez LA. Low morbidity and mortality of status epilepticus in children. Pediatrics 1989 83 : 323 31.
3. Gastaut H. Classification of status epilepticus. Adv. Neurol. 1983 34 : 15 35.
4. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989 30 : 389 99.
5. Convulsions (status epilepticus). In : Advanced Life Support Group (eds). Advanced Paediatric Life Support: The Practical Approach, 2nd edn. BMJ Publishing Group, London, 1997 113 18.
6. Vezzani A, Granata T. Brain inflammation in epilepsy: Experimental and clinical evidence. Epilepsia 2005 46 : 1724 43.
7. Pachter JS, de Vries HE, Fabry Z. The blood-brain barrier and its role in immune privilege in the central nervous system. J. Neuropathol. Exp. Neurol. 2003 62 : 593 604.
8. Webb AA, Muir GD. The blood-brain barrier and its role in inflammation. J. Vet. Intern. Med. 2000 14 : 399 11.
9. Lossinsky AS, Shivers RR. Structural pathways for macromolecular and cellular transport across the blood-brain barrier during inflammatory conditions. Histol. Histopathol. 2004 19 : 535 64.
10. Hattori H. Spontaneous remission of spasms in West syndrome: Implications of viral infection. Brain Dev. 2001 23 : 705 7.
11. Maldonado M, Baybis M, Newman D et al. Expression of ICAM-1, TNF-alpha, NF kappa B, and MAP kinase in tubers of the tuberous sclerosis complex. Neurobiol. Dis. 2003 14 : 279 90.
12. Ragsdale DS, McPhee JC, Scheuer T, Catterall WA. Common molecular determinants of local anesthetic, antiarrhythmic, and anticonvulsant block of voltage-gated Na+ channels. Proc. Natl Acad. Sci. USA 1996 93 : 9270 75.
13. Bernhard GC, Bohm E, Hojeberg S. A new treatment of status epilepticus: Intravenous injections of a local anaesthetic (lidocaine). Arch. Neurol. Psychiatry 1955 74 : 208 14.
14. Aggarwal P, Wali JP. Lidocaine in refractory status epilepticus: A forgotten drug in the emergency department. Am. J. Emerg. Med. 1993 11 : 243 4.
15. Lemmen LJ, Klassen M, Duiser B. Intravenous lidocaine in the treatment of convulsions. JAMA 1978 239 : 2025.
16. Hellstrom-Westas L, Westgren U, Rosen I, Svenningsen NW. Lidocaine for treatment of severe seizures in newborn infants. I. Clinical effects and cerebral electrical activity monitoring. Acta Paediatr. Scand. 1988 77 : 79 84.
17. Sugiyama N, Hamano S, Mochizuki M, Tanaka M, Eto Y. Efficacy of lidocaine on seizures by intravenous and intravenous-drip infusion. No To Hattatsu 2004 36 : 451 4.
18. Hamano S, Sugiyama N, Yamashita S et al. Intravenous lidocaine for status epilepticus during childhood. Dev. Med. Child Neurol. 2006 48 : 220 22.
19. Bevan S, Storey N. Modulation of sodium channels in primary afferent neurons. Novartis Found. Symp. 2002 241 : 144 53 discussion 153-8, 226 32.
20. Saab CY, Waxman SG. Potentiation of sural nerve Abeta action potential after neurogenic inflammation. Neuroreport 2004 15 : 1773 7.
21. Li Z, Inenage K, Kawano S, Kannan H, Yamashita H. Interleukin-1 beta directly excites hypothalamic supraoptic neurons in rats in vitro. Neuroreport 1992 3 : 91 3.
22. Okumura A, Tanabe T, Kato T, Hayakawa F, Watanabe K. A pilot study on lidocaine tape therapy for convulsions with mild gastroenteritis. Brain Dev. 2004 8 : 525 9.
23. DeLorenzo RJ, Towne AR, Pellock JM et al. Status epilepticus in children, adults, and the elderly. Epilepsia 1992 33 (Suppl. 4 15 25.
24. Chin RF, Neville BG, Scott RC. Meningitis is a common cause of convulsive status epilepticus with fever. Arch. Dis. Child. 2005 90 : 3 4.
25. Lossinsky AS, Shivers RR. Structural pathways for macromolecular and cellular transport across the blood-brain barrier during inflammatory conditions. Review. Histol. Histopathol. 2004 19 : 535 64.
26. Ransohoff RM, Kivisakk P, Kidd G. Three or more routes for leukocyte migration into the central nervous system. Nat. Rev. Immunol. 2003 3 : 569 81.
27. Sokic DV, Kovacevic MS. Treatment of status epilepticus with intravenous lidocaine (Xylocaine). Srp. Arh. Celok. Lek. 1989 117 : 531 8.
28. De Toledo JC. Lidocaine and seizures. Ther. Drug Monit. 2000 2 : 320 22.
29. Sawaishi Y, Yano T, Enoki M, Takada G. Lidocaine-dependent early infantile status epilepticus with highly suppressed EEG. Epilepsia 2002 43 : 201 4.
30. Walker IA, Slovis CM. Lidocaine in the treatment of status epilepticus. Acad. Emerg. Med. 1997 4 : 918 22.
31. Shorvon S. The outcome of tonic-clonic status epilepticus. Curr. Opin. Neurol. 1994 7 : 93 5.
32. Sahin M, Menache C, Holmes GL et al. Outcome of severe refractory status epilepticus in children. Epilepsia 2001 42 : 1461 7.
33. Gilbert DL, Gartside PS, Glauser TA. Efficacy and mortality in treatment of refractory generalized convulsive status epilepticus in children: A meta-analysis. J. Child Neurol. 1999 14 : 602 9.